About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
EventsCardiawave will participate in the 2nd edition of the HIFUture symposium – Apr. 21 – Lyon Apr 20, 2023 READ MORE
EventsCardiawave will be presenting at the combined ISTU/EUFUS Symposium – Apr. 18 – Lyon Apr 18, 2023 READ MORE
Press ReleaseCardiawave lauréate de la première promotion French Tech Health20 Apr 14, 2023 READ MORE
EventsCardiawave présente à la 8ème édition de la « Journée start-up innovantes du dispositif médical » – Apr. 4 – Paris Apr 13, 2023 READ MORE
About UsCardiawave est lauréate de la première promotion du French Tech Health20 ! Mar 27, 2023 READ MORE
Clinical Studies2 patients treated last week in our new clinical study site OLVG! Mar 15, 2023 READ MORE
Clinical Studies20 patients treated in our on-going European Valvosoft® Pivotal Study ! Feb 27, 2023 READ MORE
Press ReleaseCardiawave granted 3 new patents extending its intellectual property protection for its technology in the United States Feb 14, 2023 READ MORE
About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
